Bambusa Therapeutics, Inc. (NASDAQ:BBTX)
| Market Cap | 796.19M+6.7% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 49.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 433,193 |
| Open | 14.97 |
| Previous Close | 14.99 |
| Day's Range | 14.82 - 16.06 |
| 52-Week Range | 13.60 - 16.06 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
1 qualifying trade · 1 insider · $12.00M bought in the last 90 days
About BBTX
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Ask Barron about BBTX
$BBTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BBTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BBTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BBTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BBTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BBTX from public contracts
Source: USAspending.gov
BBTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BBTX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #14 of 97 scored Biotech stocks · sector average 59.5